Knowledge of patients undergoing long-term acenocumarol treatment about the safety of anticoagulant therapy;Wiedza o zasadach bezpiecznego stosowania doustnych antykoagulantów u chorych leczonych przewlekle acenokumarolem

Polski Merkuriusz Lekarski

Volumn 22, Issue 127, 2007, Pages 36-40

  Sawicka Powierza, Jolanta ^a,b   Tarzewska, Alicja MaŁgorzata Oł ^a   Chlabicz, SŁawomir ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Zak ad Medycyny Rodzinnej i Piel gniarstwa rodowiskoweao   (Poland)

Author keywords

Acenocumarol; Oral anticoagulants; Patients' education

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT;

ARTICLE; ATTITUDE TO HEALTH; CHRONIC DISEASE; DRUG ADMINISTRATION; DRUG INTERACTION; EDUCATION; EVALUATION; HERB DRUG INTERACTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT EDUCATION; POLAND; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SELF CARE; STATISTICS; VEIN THROMBOSIS;

ACENOCOUMAROL; ANTICOAGULANTS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EDUCATIONAL MEASUREMENT; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HERB-DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; PATIENT EDUCATION; POLAND; QUESTIONNAIRES; SELF CARE; VENOUS THROMBOSIS;

EID: 33847034728     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ansell J., Hirsh J., Poller L. i wsp.: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest., 2004, 126, suppl. 3, 204S-233S.
2. Ansell J., Jacobson A., Levy J. i wsp.: Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int. J. Cardiol., 2005, 99, 1, 37-45.
3. Ansell J. E., Buttaro M.L., Thomas O.V. i wsp.: Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ann. Pharmacother., 1997, 31, 5, 604-615.
4. Barcellona D., Contu P., Marongiu F.: Patient education and oral anticoagulant therapy. Haematologica, 2002, 87, 10, 1081-1086.
5. Brown C.H. 3rd, Natelson E.A., Bradshaw W. i wsp.: The hemostatic defect produced by carbenicillin. N. Engl. J. Med., 1974, 291, 6, 265-270.
6. Couris R.R., Tataronis G.R., Dallai G.E. i wsp.: Assessment of healthcare professionals' knowledge about warfarin-vitamin K drug-nutrient interactions. J. Am. Coll. Nutr., 2000, 19, 4, 439-445.
7. Dale J., Myhre E., Loew D.: Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am. Heart. J., 1980, 99, 6, 746-752.
8. Davis N.J., Billett H.H., Cohen H.W. i wsp.: Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann. Pharmacother., 2005, 39, 4, 632-636.
9. Gage B.F., Fihn S.D., White R.H.: Management and dosing of warfarin therapy. Am. J. Med., 2000, 109, 6, 481-488.
10. Gage B.F., Milligan P.E.: Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. Thromb. Res., 2005, 117, 1-2, 55-59.
11. Garcia A., Marin F., Sanchez B. i wsp.: Diurnal variation in the intensity of anticoagulation in atrial fibrillation. Stroke, 2002, 33, 1, 322-324.
12. Geerts W.H., Pineo G.F., Heit J.A. i wsp.: Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest., 2004, 126, suppl. 3, 338S-400S.
13. Harris J.E.: Interaction of dietary factors with oral anticoagulants: review and applications. J. Am. Diet. Assoc., 1995, 95, 5, 580-584.
14. Higashi MX., Veenstra D.L., Kondo L.M. i wsp.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA., 2002, 287, 13, 1690-1698.
15. Hirsh J., Dalen J., Anderson D.R. i wsp.: Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest., 2001, 119, suppl. 1, 8S-21S.
16. Ho C.H., Lin M.W., You J.Y. i wsp.: Variations of prothrombin time and international normalized ratio in patients treated with warfarin. Thromb. Res., 2002, 107, 5, 277-280.
17. Kortke H., Korfer R.: International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?. Ann. Thorac. Surg., 2001, 72, 1, 44-48.
18. Lane D.A., Ponsford J., Shelley A. i wsp.: Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int. J. Cardiol., 2006, 110, 3, 354-358.
19. Mahe I., Grenard A.S., Joyeux N. i wsp.: Management of oral anticoagulant in clinical practice: a retrospective study of 187 patients. J. Gerontol. A. Biol. Sci. Med. Sci., 2004, 59, 12, 1339-1342.
20. Mannucci P.M.: Genetic control of anticoagulation. Lancet, 1999, 353, 9154, 688-689.
21. Marder V.J.: The interaction of dietary supplements with antithrombotic agents: Scope of the problem. Thromb. Res., 2005, 117, 1-2, 7-13.
22. McCormack P.M., Stinson J.C., Hemeryck L. i wsp.: Audit of an anticoagulant clinic: doctor and patient knowledge. Ir. Med. J., 1997, 90, 5, 192-193.
23. O'Reilly R.A.: Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch . Intern. Med., 1981, 141, 4, 458-459.
24. O'Reilly R.A.: Studies on the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther., 1974, 16, 2, 348-354.
25. O'Reilly R.A.: The stereoselective interaction of warfarin and metronidazole in man. N. Engl. J. Med., 1976, 295, 7, 354-357.
26. Psuja P.: Konieczność edukacji chorych leczonych doustnym antykoagulantem. Acta. Haematol. Pol., 2001, 32, suppl. 1, 220-227.
27. Roche-Nagle G., Chambers F., Nanra J. i wsp.: Evaluation of patient knowledge regarding oral anticoagulants. Ir. Med. J., 2003, 96, 7, 211-213.
28. Rosendaal F.R.: The Scylla and Charybdis of oral anticoagulant treatment. N. Engl. J. Med., 1996, 335, 8, 587-589.
29. Roth G.J., Majerus P.W.: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J. Clin. Invest., 1975, 56, 3, 624-632.
30. Rothschild B.M.: Hematologic perturbations associated with salicylate. Clin. Pharmacol. Ther., 1979, 26, 2, 145-152.
31. Saligari E., Belle L., Berry C. i wsp.: Evaluation of an education program of patients undergoing oral anticoagulation treatment. Ann. Cardiol. Angeiol. (Paris)., 2003, 52, 5, 297-301.
32. Sadowski J.A., Suttie J.W.: Mechanism of action of coumarins. Significance of vitamin K epoxide. Biochemistry., 1974, 13, 18, 3696-3699.
33. Sawicki P.T.: A structured teaching and self management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA, 1999, 281, 2, 145-150.
34. Schulman S., Henriksson K.: Interaction of ibuprofen and warfarin on primary haemostasis. Br. J. Rheumatol., 1989, 28, 1, 46-49.
35. Tang E.O., Lai C.S., Lee K.K. i wsp.: Relationship between patients' warfarin knowledge and anticoagulation control. Ann. Pharmacother., 2003, 37, 1, 34-39.
36. Thijssen H.H., Hamulyak K., Willigers H.: 4-Hydroxycoumarin oral anti-coagulants: pharmacokinetics-response relationship. Thromb. Haemost., 1988, 60, 1, 35-38.
37. Weitekamp M.R., Aber R.C.: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA, 1983, 249, 1, 69-71.
38. Wells P.S., Holbrook A.M., Crowther N.R. i wsp.: Interactions of warfarin with drugs and food. Ann. Intern. Med., 1994, 121, 9, 676-683.
39. Williams G.O.: Management of depression in the elderly. Prim. Care., 1989. 16, 2, 451-474.
40. Wilson S.J., Wells P.S., Kovacs M.J. i wsp.: Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ, 2003, 169, 4, 293-298.
41. Wittkowsky A.K.: A systematic review and inventory of supplement effects on warfarin and other anticoagulants. Thromb. Res., 2005, 117, 1-2, 81-86.
42. Wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Grupa Robocza ekspertów w dziedzinie profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej oraz w dziedzinie metodologii tworzenia wytycznych. Med. Prakt., 2005, suppl. do 6 (172).